2023 IS the Year for OTC Naloxone!
FDA Law Blog: Biosimilars
MARCH 29, 2023
Emergent will need time to manufacture and distribute NNS with the new OTC labeling, so the public should not expect to be able to walk into their local pharmacy and grab a box off the shelf in the coming days. According to this announcement, FDA approval of RiVive is anticipated in July 2023 and the U.S.
Let's personalize your content